kabutan

Noile-Immune Biotech Inc., The Current Fiscal Year's Undisclosed Net Income to Narrow

Thu Nov 14, 2024 3:30 pm JST Earnings

4893 Noile-Immune Biotech Inc. 【J-GAAP】

Earnings Report

Noile-Immune Biotech Inc. <4893> [TSE-G] announced its financial results after the market closed on November 14th (15:30). The net loss (non-consolidated) for the cumulative third quarter of the fiscal year ending December 2024 (January to September) was a reduced loss of 787 million yen (compared to a loss of 850 million yen in the same period last year).

In addition, the full-year forecast, which was not disclosed, indicated that net loss further decrease to loss of 994 million yen (compared to a loss of 1.13 billion yen in the previous period).

Based on the third-quarter cumulative performance announced by the company and the full-year plan, our calculation indicates that the net loss for the October to December period (4Q) is expected to further decrease to loss of 207 million yen (compared to a loss of 280 million yen in the same period last year).

In the most recent three-month period, from July to September (3Q), the net loss expanded to a loss of 104 million yen (compared to a loss of 17 million yen in the same period last year). The operating profit/loss margin drastically worsened from -4.6% in the same period last year to -7033.3%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Jan - Sep, 2023 314 -495 -848 -850 -20.8 ー Nov 13, 2023 J-GAAP
Jan - Sep, 2024 5 -892 -785 -787 -18.2 ー Nov 14, 2024 J-GAAP
YoY -98.4% -80.2% +7.4% +7.4% +12.6%

Guidance Update

Second Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jul - Dec, 2024 Prev ー ー ー ー － 0 Feb 13, 2024 J-GAAP
Jul - Dec, 2024 New 5 -418 -309 -311 -7.2 0 Nov 14, 2024 J-GAAP
Revision Rate － － － － －

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2024 Prev ー ー ー ー － 0 Feb 13, 2024 J-GAAP
Dec, 2024 New 7 -1,099 -991 -994 -23.0 0 Nov 14, 2024 J-GAAP
Revision Rate － － － － －

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jul - Dec, 2023 305 -294 -295 -297 -7.2 0 Feb 13, 2024 J-GAAP
Jul - Dec, 2024 Guidance 5 -418 -309 -311 -7.2 0 Nov 14, 2024 J-GAAP
YoY -98.4% -42.2% -4.7% -4.7% -0.3%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2023 316 -775 -1,127 -1,130 -27.3 0 Feb 13, 2024 J-GAAP
Dec, 2024 Guidance 7 -1,099 -991 -994 -23.0 0 Nov 14, 2024 J-GAAP
YoY -97.8% -41.8% +12.1% +12.0% +15.7%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2023 303 -14 -16 -17 -0.4 -4.6 Nov 13, 2023 J-GAAP
Oct - Dec, 2023 2 -280 -279 -280 -6.8 -14,000.0 Feb 13, 2024 J-GAAP
Jan - Mar, 2024 2 -339 -339 -340 -7.9 -16,950.0 May 14, 2024 J-GAAP
Apr - Jun, 2024 0 -342 -343 -343 -7.9 -Inf Aug 9, 2024 J-GAAP
Jul - Sep, 2024 3 -211 -103 -104 -2.4 -7,033.3 Nov 14, 2024 J-GAAP
YoY -99.0% -1,407.1% -543.8% -511.8% -471.4%

Related Articles